



COVID-19: KEEPING UP WITH A MOVING TARGET

Aug 19, 2020 UPDATE



Paul Auwaerter, MD, MBA, FIDSA
Clinical Director, Division of Infectious Diseases
Sherrilyn and Ken Fisher Professor of Medicine
Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine



Postgraduate Institute
for Medicine



JOHNS HOPKINS
NURSING





CME Information

Jointly provided by Postgraduate Institute for Medicine, DKBmed, and the Institute for Johns Hopkins Nursing.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or Presenter	Reported Financial Relationship
Paul G. Auwaerter, MD, MBA, FIDSA	Scientific Advisor: DiaSorin, Shionogi Inc. JNJ: Ownership equity

Dr. Auwaerter has indicated that he will be referencing the unlabeled or unapproved use of agents currently being investigated in on-going studies and trials. These include dexamethasone, COVID-19 convalescent plasma and vaccine platforms.

All activity, content, and materials have been developed solely by the activity directors, planning committee members, and faculty presenters, and are free of influence from a commercial entity.





CME Information

To attest for CME/CE/AAPA credit, please visit
COVID19.dkbmed.com





Learning Objectives

- Describe how efficacy will be measured in vaccine studies
- Discuss accuracy of currently used COVID diagnostic and antibody tests
- Describe efficacy of face shields relative to that of face masks





Thank You

This activity is supported by an educational grant from Pfizer, Inc. and in-kind support by DKBmed, LLC.

All activity content and materials have been developed solely by the activity directors, planning committee members, and faculty presenters.

Please see **COVID19.DKBmed.com** for additional resources and educational activities





Paul Auwaerter, MD, MBA, FIDSA
Clinical Director, Division of Infectious Diseases
Sherrilyn and Ken Fisher Professor of Medicine
Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine





To submit your own question, please email QA@dkbmed.com





For the phase 3 trials of vaccines, how is efficacy being measured?

In addition to antibody presence to COVID-19, will the subjects be exposed to the virus?





Is it harmful to keep using inhalers to control a cough that is thought to be due to asthma when it may be a symptom of COVID-19?





Plastic face shields are being considered an alternative to wearing masks in some elementary and secondary schools. Would you comment on the efficacy of face shields compared to masks in public settings?





Vaccines in development report an expected protection rate of 50-70%. Is this as good as it gets?





You mentioned dexamethasone as a standard of care for patients on vents. Is it a standard of care for patients on oxygen?





For the phase 3 trials of vaccines, how is efficacy being measured?

In addition to antibody presence to COVID-19, will the subjects be exposed to the virus?





Is it true that people are most infectious in the 48 hours before their symptoms appear?





How accurate are the COVID-19 diagnostic and antibody tests that are currently in use?





If we don't have access to influenza testing and we are treating all viral symptomology as if it were COVID-19, should these individuals self-quarantine for 14 days before being allowed back in classes?





If we don't have access to influenza testing and we are treating all viral symptomology as if it were COVID-19, should these individuals self-quarantine for 14 days before being allowed back in classes?





To receive CME/CE/AAPA credit:

- Complete the evaluation on at COVID19.DKBmed.com
- Upon registering and successfully completing the activity evaluation, you will have immediate access to your certificate.

To access more resources related to COVID-19:

- Access our resource hub at COVID19.DKBmed.com

To ask your own question, email: QA@dkbmed.com

